


RESEARCH REPORT



GENOMIC CANCER PANEL AND PROFILING MARKETS BY CANCER, BY APPLICATION, BY TISSUE AND BY GENE TYPE WITH SCREENING POTENTIAL MARKET SIZE, CUSTOMIZED FORECASTING/ANALYSIS, AND EXECUTIVE AND CONSULTANT GUIDES 2022-2026





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1	Market Guides	25
1.1	Cancer Panel Market - Strategic Situation Analysis & COVID Update.....	26
1.2	Large Comprehensive Cancer Panel Market - Situation Analysis	28
1.3	Guide for Executives, Marketing, Sales and Business Development Staff	30
1.4	Guide for Management Consultants and Investment Advisors.....	32
1.5	Market Size and Shares – Large Comprehensive	33
2	Introduction and Market Definition	35
2.1	What are Cancer Gene Panels and Profiling?	36
2.2	The Sequencing Revolution	39
2.3	Market Definition	41
2.3.1	Revenue Market Size.....	41
2.4	Methodology.....	42
2.4.1	Authors	42
2.4.2	Sources	43
2.5	Perspective: Healthcare and the IVD Industry	44
2.5.1	Global Healthcare Spending	44
2.5.2	Spending on Diagnostics	45
2.5.3	Important Role of Insurance for Diagnostics	46
3	Market Overview.....	48

3.1	Players in a Dynamic Market.....	49
3.1.1	Academic Research Lab	50
3.1.2	Diagnostic Test Developer.....	50
3.1.3	Instrumentation Supplier	50
3.1.4	Distributor and Reagent Supplier	51
3.1.5	Independent Testing Lab.....	51
3.1.6	Public National/regional lab	52
3.1.7	Hospital lab	52
3.1.8	Physician Office Labs	53
3.1.9	Audit Body	53
3.1.10	Certification Body.....	53
3.2	Oncogenomics	55
3.2.1	Carcinogenesis.....	55
3.2.2	Chromosomes, Genes and Epigenetics.....	57
3.2.2.1	Chromosomes.....	57
3.2.2.2	Genes	59
3.2.2.3	Epigenetics.....	62
3.2.3	Cancer Genes.....	63
3.2.4	Germline vs Somatic	65
3.2.5	Gene Panels, Single Gene Assays and Multiplexing	66
3.2.6	Genomic Profiling.....	67
3.2.7	The Comprehensive Assay	68
3.2.8	Changing Clinical Role	68
3.2.9	The Cancer Screening Market Opportunity.....	70

- 3.3 Cancer Management vs. Diagnosis..... 71
 - 3.3.1 The Role of Risk Assessment 71
 - 3.3.2 Diagnosis 71
 - 3.3.3 Managing 72
 - 3.3.4 Monitoring..... 72
- 3.4 Phases of Adoption – Looking into The Future 73
- 3.5 Structure of Industry Plays a Part..... 74
 - 3.5.1 Hospital Testing Share 74
 - 3.5.2 Economies of Scale..... 74
 - 3.5.2.1 Hospital vs. Central Lab..... 75
 - 3.5.3 Physician Office Lab's..... 76
 - 3.5.4 Physician's and POCT 77
- 3.6 Currently Available Large Comprehensive Assays 77
- 3.7 Pricing Profiling vs. Whole Exome (or Genome) Sequencing..... 80
 - 3.7.1 Medicare Profile Pricing..... 80
 - 3.7.2 Whole Exome Sequencing 80
- 4 Market Trends82
 - 4.1 Factors Driving Growth 83
 - 4.1.1 Level of Care 83
 - 4.1.2 Companion Dx 84
 - 4.1.3 Immuno-oncology..... 84
 - 4.1.4 Liability..... 84
 - 4.1.5 Aging Population..... 84
 - 4.2 Factors Limiting Growth 86

4.2.1	State of knowledge.....	86
4.2.2	Genetic Blizzard.....	87
4.2.3	Protocol Resistance.....	87
4.2.4	Regulation and coverage.....	87
4.3	Instrumentation and Automation.....	88
4.3.1	Instruments Key to Market Share.....	88
4.3.2	Bioinformatics Plays a Role.....	88
4.4	Diagnostic Technology Development.....	89
4.4.1	Next Generation Sequencing Fuels a Revolution.....	90
4.4.2	Single Cell Genomics Changes the Picture.....	91
4.4.3	Pharmacogenomics Blurs Diagnosis and Treatment.....	92
4.4.4	CGES Testing, A Brave New World.....	92
4.4.5	Biochips/Giant magneto resistance based assay.....	93
5	Cancer Panels & Profiles Recent Developments.....	94
5.1	Recent Developments – Importance and How to Use This Section.....	95
5.1.1	Importance of These Developments.....	95
5.1.2	How to Use This Section.....	95
5.2	Genetron Health Adds New Assays to Pipeline.....	95
5.3	Illumina Obtains CE-IVD Marking for TSO Comprehensive Assay.....	98
5.4	Guardant Health Receives Medicare Coverage for Guardant360 TissueNext™ Test ...	99
5.5	Cancer Screening Launch Approaches, Guardant Health Plans New Comprehensive Assay.....	100
5.6	Thermo Fisher, Oncocyte Ink Deal for Cancer IVDs.....	102
5.7	Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep Major Role.....	104

5.8	Labcorp, CCORN Partner for Precision Oncology	111
5.9	Dante Labs Acquires Cambridge Cancer Genomics	112
5.10	Celemics, Strand Partner on Integrated Platform for NGS Analysis	113
5.11	Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries	113
5.12	Burning Rock Revenues Rise	119
5.13	Caris Life Sciences to Expand Liquid Biopsy Testing	121
5.14	OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence.....	124
5.15	Intermountain and Myriad Combine Test Offering	128
5.16	Illumina, Geneseeq to Offer Cancer Testing Kits in China.....	133
5.17	Exact Sciences to Offer End-to-End Cancer Testing	134
5.18	Guardant Health Turns to Tumor Tissue Sequencing	137
5.19	Tempus Inks Oncology Testing Collaboration With Bayer.....	141
5.20	Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform 142	
5.21	Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test	143
5.22	Metastatic Cancer Markers Identified in Clinical WGS Study.....	144
5.23	Stitch Bio Bets on CRISPR Tech	147
5.24	Bayer, LifeLabs Launch Free NTRK Genetic Testing Program	151
5.25	Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx 152	
5.26	Progress, Challenges in Liquid Biopsy Reimbursement.....	153
5.27	Israeli Startup Curesponse Raises \$6M.....	157
5.28	Invitae, ArcherDX Merge to Advance Precision Oncology Offerings	158
5.29	MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution 159	

5.30	NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program.....	159
5.31	Germline Results Guides Precision Therapy in Advanced Cancer	160
5.32	FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics	165
5.33	ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers 166	
5.34	Labs Reporting Cancer Risk Mutations from Tumor Testing	167
5.35	Users Begin Integrating Genomics Data for Clinical Decision Support.....	175
5.36	Fujitsu Improves Efficiency in Cancer Genomic Medicine	180
5.37	Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results	182
5.38	Universal Genetic Testing for All Breast Cancer Patients	183
5.39	Exact Sciences buys Genomic Health	184
5.40	Multi-Gene Liquid Biopsy Breast Cancer Panel	186
5.41	Thrive to Develop Earlier Detection of Multiple Cancer Types.....	186
5.42	New Gene Panel Identifies High Risk Prostate Cancer	188
5.43	Guardant Health Liquid Biopsy Test to be Covered by EviCore	190
5.44	Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services.....	191
5.45	Natera Commercializes Tumor Whole Exome Sequencing from Plasma.....	192
5.46	Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance	193
6	Profiles of Key Players.....	195
6.1	10x Genomics, Inc.....	196
6.2	Abbott Diagnostics	197
6.3	AccuraGen Inc.	199
6.4	Adaptive Biotechnologies.....	200
6.5	Aethlon Medical	201

6.6	Agena Bioscience, Inc.	202
6.7	Agilent/Dako	204
6.8	Anchor Dx.....	206
6.9	ANGLE plc.....	207
6.10	ApoCell, Inc.....	208
6.11	ArcherDx, Inc.....	209
6.12	ARUP Laboratories.....	210
6.13	Asuragen.....	212
6.14	AVIVA Biosciences	214
6.15	Baylor Miraca Genetics Laboratories	215
6.16	Beckman Coulter Diagnostics.....	216
6.17	Becton, Dickinson and Company	217
6.18	BGI Genomics Co. Ltd	219
6.19	Bioarray Genetics.....	221
6.20	Biocartis	222
6.21	Biocept, Inc.....	223
6.22	Biodesix Inc.	225
6.23	BioFluidica.....	226
6.24	BioGenex	227
6.25	BioIVT	229
6.26	Biolidics Ltd.....	230
6.27	bioMérieux Diagnostics.....	231
6.28	Bioneer Corporation	233
6.29	Bio-Rad Laboratories, Inc.....	235

6.30	Bio-Reference Laboratories.....	237
6.31	Bio-Techne	238
6.32	Bioview	239
6.33	Bolidics	240
6.34	Boreal Genomics.....	241
6.35	Bristol-Myers Squibb.....	242
6.36	Burning Rock.....	244
6.37	Cancer Genetics.....	245
6.38	Caris Molecular Diagnostics	247
6.39	Castle Biosciences, Inc.	248
6.40	Celemics	249
6.41	CellMax Life	250
6.42	Cepheid (Danaher)	251
6.43	Charles River Laboratories.....	253
6.44	Chronix Biomedical	254
6.45	Circulogene.....	255
6.46	Clinical Genomics	256
6.47	Cynvenio.....	257
6.48	Cytolumina Technologies Corp.	258
6.49	CytoTrack.....	259
6.50	Datar Cancer Genetics Limited.....	260
6.51	Diagnologix LLC.....	261
6.52	Diasorin S.p.A.....	262
6.53	Enzo Life Sciences, Inc.	264

6.54	Epic Sciences.....	266
6.55	Epigenomics AG.....	267
6.56	Eurofins Scientific	268
6.57	Exact Sciences	270
6.58	Exosome Diagnostics	271
6.59	Exosome Sciences.....	272
6.60	Fabric Genomics	273
6.61	Fluidigm Corp	274
6.62	Fluxion Biosciences.....	275
6.63	Foundation Medicine	276
6.64	Freonome.....	277
6.65	FUJIFILM Wako Diagnostics.....	278
6.66	GeneFirst Ltd.....	279
6.67	Genetron Holdings	280
6.68	GenomOncology.....	281
6.69	GILUPI Nanomedizin.....	282
6.70	Grail, Inc.....	283
6.71	Guardant Health	284
6.72	HaliuDx	285
6.73	HansaBiomed	286
6.74	HeiScreen.....	287
6.75	Helomics.....	288
6.76	Horizon Discovery	289
6.77	HTG Molecular Diagnostics	291

6.78	iCellate.....	292
6.79	Illumina	293
6.80	Incell Dx.....	294
6.81	Inivata	295
6.82	Integrated Diagnostics	296
6.83	Invitae Corporation.....	297
6.84	Invivogen	299
6.85	Invivoscribe	300
6.86	Janssen Diagnostics	301
6.87	MDNA Life SCIENCES, Inc.....	302
6.88	MDx Health	303
6.89	Menarini Silicon Biosystems.....	304
6.90	Millipore Sigma	305
6.91	Miltenyi Biotec	306
6.92	MIODx.....	307
6.93	miR Scientific.....	308
6.94	Molecular MD	309
6.95	MyCartis	310
6.96	Myriad Genetics/Myriad RBM	311
6.97	NantHealth, Inc.	312
6.98	Natera	313
6.99	NeoGenomics	314
6.100	New Oncology.....	315
6.101	NGeneBio.....	316

6.102	Novogene Bioinformatics Technology Co., Ltd.....	318
6.103	Oncocyte.....	320
6.104	OncoDNA	321
6.105	Ortho Clinical Diagnostics	322
6.106	Oxford Nanopore Technologies	323
6.107	Panagene.....	324
6.108	Perkin Elmer.....	325
6.109	Personal Genome Diagnostics.....	327
6.110	Personalis.....	328
6.111	Precipio	329
6.112	PrecisionMed	330
6.113	Promega	331
6.114	Qiagen Gmbh	333
6.115	Rarecells SAS.....	335
6.116	RareCyte.....	336
6.117	Roche Molecular Diagnostics	337
6.118	Screencell	339
6.119	Sense Biodetection	340
6.120	Serametrix	341
6.121	Siemens Healthineers	342
6.122	Silicon Biosystems.....	344
6.123	simfo GmbH	345
6.124	Singlera Genomics Inc.....	346
6.125	Singulomics	347

6.126	SkylineDx	349
6.127	Stratos Genomics	350
6.128	Sysmex Inostics.....	351
6.129	Tempus Labs, Inc.	352
6.130	Thermo Fisher Scientific Inc.....	353
6.131	Thrive Earlier Detection	356
6.132	Todos Medical	357
6.133	Trovagene.....	358
6.134	Variantyx	359
6.135	Volition	360
6.136	Vortex Biosciences	361
7	The Global Market for Cancer Gene Panels and Profiles.....	362
7.1	Global Market Overview by Country	363
7.1.1	Table – Global Market by Country.....	363
7.1.2	Chart - Global Market by Country	364
7.2	Global Market by Cancer Type - Overview.....	365
7.2.1	Table – Global Market by Cancer Type	365
7.2.2	Chart – Global Market by Cancer Type – Base/Final Year Comparison	366
7.2.3	Chart – Global Market by Cancer Type – Base Year	367
7.2.4	Chart – Global Market by Cancer Type – Final Year.....	368
7.2.5	Chart – Global Market by Cancer Type – Share by Year	369
7.2.6	Chart – Global Market by Cancer Type – Segment Growth	370
7.3	Global Market by Application - Overview.....	371
7.3.1	Table – Global Market by Application	371

7.3.2	Chart – Global Market by Application – Base/Final Year Comparison	372
7.3.3	Chart – Global Market by Application – Base Year	373
7.3.4	Chart – Global Market by Application – Final Year	374
7.3.5	Chart – Global Market by Application – Share by Year.....	375
7.3.6	Chart – Global Market by Application – Segment Growth	376
7.4	Global Market by Tissue - Overview	377
7.4.1	Table – Global Market by Tissue	377
7.4.2	Chart – Global Market by Tissue – Base/Final Year Comparison	378
7.4.3	Chart – Global Market by Tissue – Base Year	379
7.4.4	Chart – Global Market by Tissue – Final Year	380
7.4.5	Chart – Global Market by Tissue – Share by Year	381
7.4.6	Chart – Global Market by Tissue – Segment Growth.....	382
7.5	Global Market Germline & Somatic - Overview.....	383
7.5.1	Table – Global Market Germline & Somatic	383
7.5.2	Chart – Global Market Germline & Somatic – Base/Final Year Comparison	384
7.5.3	Chart – Global Market Germline & Somatic – Base Year	385
7.5.4	Chart – Global Market Germline & Somatic – Final Year.....	386
7.5.5	Chart – Global Market Germline & Somatic – Share by Year.....	387
7.5.6	Chart – Global Market Germline & Somatic – Segment Growth	388
8	Global Cancer Gene Panels & Profiles Markets – By Type of Cancer.....	389
8.1	Comprehensive Panels & Profiles	390
8.1.1	Table Comprehensive Testing – by Country.....	390
8.1.2	Chart - Comprehensive Testing Growth.....	391
8.2	Breast Cancer Gene Testing	392

8.2.1	Table Breast Cancer Gene Testing – by Country	392
8.2.2	Chart - Breast Cancer Testing Growth.....	393
8.3	Colorectal Cancer Gene Testing	394
8.3.1	Table Colorectal Cancer Gene Testing – by Country.....	394
8.3.2	Chart - Colorectal Cancer Gene Testing Growth	395
8.4	Gynecological Cancer Gene Testing	396
8.4.1	Table Gynecological Cancer Gene Testing – by Country	396
8.4.2	Chart - Gynecological Cancer Gene Testing Growth.....	397
8.5	Blood Cancer Gene Testing.....	398
8.5.1	Table Blood Cancer Gene Testing – by Country	398
8.5.2	Chart - Blood Cancer Gene Testing Growth	399
8.6	Prostate Cancer Gene Testing.....	400
8.6.1	Table Prostate Cancer Gene Testing – by Country	400
8.6.2	Chart - Prostate Cancer Testing Growth	401
8.7	Lung Cancer Gene Testing	402
8.7.1	Table Lung Cancer Gene Testing – by Country.....	402
8.7.2	Chart - Lung Cancer Gene Testing Growth.....	403
8.8	Other Cancer Gene Testing.....	404
8.8.1	Table Other Cancer Gene Testing – by Country	404
8.8.2	Chart - Other Cancer Gene Testing Growth	405
9	Global Cancer Gene Panels & Profiles Markets – By Type of Application	406
9.1	Clinical Testing.....	407
9.1.1	Table Clinical Testing – by Country	407
9.1.2	Chart - Clinical Testing Growth.....	408

9.2	Pharmaceutical Testing.....	409
9.2.1	Table Pharmaceutical Testing – by Country	409
9.2.2	Chart - Pharmaceutical Testing Growth.....	410
9.3	Research Testing	411
9.3.1	Table Research Testing – by Country.....	411
9.3.2	Chart - Research Testing Growth	412
10	Global Cancer Gene Panels & Profiles Markets – By Tissue Type.....	413
10.1	Solid Tissue.....	414
10.1.1	Table Solid Tissue Testing – by Country	414
10.1.2	Chart – Solid Tissue Testing Growth	415
10.2	Liquid Tissue Testing	416
10.2.1	Table Liquid Tissue Testing – by Country	416
10.2.2	Chart - Liquid Tissue Testing Growth.....	417
11	Global Cancer Gene Testing Markets – Germline and Somatic	418
11.1	Global Market Somatic.....	419
11.1.1	Table Somatic – by Country	419
11.1.2	Chart - Somatic Testing Growth	420
11.2	Global Market Germline.....	421
11.2.1	Table Germline – by Country.....	421
11.2.2	Chart - Germline Testing Growth	422
12	Potential Market Opportunity Sizes.....	423
12.1	Potential Cancer Screening by Country: Lung, Breast & Colorectal.....	424
12.2	Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer.....	426
12.3	Potential Market Size - Cancer Diagnosis.....	428

12.4 Potential Market Size – Therapy Selection..... 430

13 Appendices432

13.1 Quarterly Actuals and Forecast Volumes and Revenues for Foundation Medicine and Guardant Health 433

13.2 United States Medicare System: January 2022 Clinical Laboratory Fees Schedule . 438

13.3 FDA Approved Human Genetic Tests..... 540

13.4 Pharmacogenomic Biomarkers in Drug Labeling..... 546

13.5 FDA Approved Pharmacogenomics Tests 569

Table of Tables

Table 1 Market Shares	33
Table 2 Market Players by Type	49
Table 3 The Base Pairs.....	60
Table 4 Current Assays	77
Table 5 Relevant Pricing Table	80
Table 6 Five Factors Driving Growth.....	83
Table 7 Four Factors Limiting Growth	86
Table 8 Key Diagnostic Laboratory Technology Trends	89
Table 9 Next Generation Sequencing Technologies – Speed and Cost	90
Table 10 - Global Cancer Panel Market by Region.....	363
Table 11 Global Market by Cancer Type	365
Table 12 Global Market by Application.....	371
Table 13 Global Market by Tissue	377
Table 14 Global Market Germline & Somatic	383
Table 15 Comprehensive Testing by Country.....	390
Table 16 Breast Cancer Gene Testing by Country.....	392
Table 17 Colorectal Cancer Gene Testing by Country.....	394
Table 18 Gynecological Cancer Testing by Country	396
Table 19 Blood Cancer Gene Testing by Country	398
Table 20 Prostate Cancer Gene Testing by Country	400
Table 21 Lung Cancer Gene Testing by Country.....	402

Table 22 Other Cancer Gene Testing by Country	404
Table 23 Clinical Testing by Country	407
Table 24 Pharmaceutical Testing by Country	409
Table 25 Research Testing by Country	411
Table 26 Solid Tissue Testing by Country.....	414
Table 27 Liquid Tissue Testing by Country	416
Table 28 Somatic by Country	419
Table 29 Germline by Country	421
Table 30 Potential Screening Market: Lung, Breast & Colorectal.....	424
Table 31 Potential Screening Market: Prostate, Other & All	426
Table 32 Potential Cancer Diagnosis Market Size	428
Table 33 Potential Cancer Management Market Size	430
Table 34 Foundation - Guardant 2016-17 Quarterly Revenue & Volume	433
Table 35 Foundation - Guardant 2018 Quarterly Revenue & Volume	434
Table 36 Foundation - Guardant 2019 Quarterly Revenue & Volume	435
Table 37 Foundation - Guardant 2020 Quarterly Revenue & Volume	436
Table 38 Foundation - Guardant 2021 Quarterly Revenue & Volume	437
Table 39 2022 Laboratory Fee Schedule	438
Table 40 FDA Approved Human Genetic tests	540
Table 41 Pharmacogenomic Biomarkers	546
Table 42 FDA Approved Pharmacogenomic Tests.....	569

Table of Figures

Figure 1 Large Comprehensive Profiles – Company Market Shares Chart	34
Figure 2 VistSeq Hereditary Cancer Panel.....	38
Figure 3 Global Healthcare Spending	45
Figure 4 The Wholesale and Retail Lab Test Pie	46
Figure 5 The Genomic Progression of Cancer.....	56
Figure 6 DNA Strands and Chromosomes	57
Figure 7 Karyogram of Human Chromosomes.....	58
Figure 8 Size of Various Genomes	61
Figure 9 Germline vs Somatic Mutations.....	65
Figure 10 Comparing Genomic Diagnostic and Traditional Testing	69
Figure 11 Percentage of World Population Over 65.....	85
Figure 12 Base Year Country Global Share	364
Figure 13 Global Market by Cancer - Base vs. Final Year	366
Figure 14 Cancer Panel Market Base Year.....	367
Figure 15 Cancer Panel Market Final Year	368
Figure 16 Cancer Type Share by Year	369
Figure 17 Cancer Type Segment Growth	370
Figure 18 Global Market by Cancer - Base vs. Final Year	372
Figure 19 Cancer Panel Market Base Year.....	373
Figure 20 Cancer Panel Market Final Year	374
Figure 21 Application Share by Year.....	375

Figure 22 Application Segment Growth	376
Figure 23 Global Market by Cancer - Base vs. Final Year	378
Figure 24 Cancer Panel Market Base Year.....	379
Figure 25 Cancer Panel Market Final Year	380
Figure 26 Tissue Share by Year	381
Figure 27 Tissue Segment Growth.....	382
Figure 28 Germline & Somatic - Base vs. Final Year	384
Figure 29 Germline & Somatic Market Base Year	385
Figure 30 Germline & Somatic Market Final Year.....	386
Figure 31 Germline & Somatic Share by Year	387
Figure 32 Germline & Somatic Segment Growth	388
Figure 33 Comprehensive Testing Growth.....	391
Figure 34 Breast Cancer Testing Growth.....	393
Figure 35 Colorectal Cancer Gene Testing Growth	395
Figure 36 Gynecological Cancer Testing Growth	397
Figure 37 Blood Cancer Gene Testing Growth	399
Figure 38 Prostate Cancer Gene Testing Growth	401
Figure 39 Lung Cancer Gene Testing Growth.....	403
Figure 40 Other Cancer Gene Testing Growth	405
Figure 41 Clinical Testing Growth	408
Figure 42 Pharmaceutical Testing Growth.....	410
Figure 43 Research Testing Growth	412
Figure 44 Solid Tissue Testing Growth.....	415
Figure 45 Liquid Tissue Testing Growth.....	417

Figure 46 Somatic Testing Growth..... 420

Figure 47 Germline Testing Growth 422